Tyco Healthcare Group LP, and Mallinckrodt Inc., v. Pharmaceutical Holdings Corp., et al.

In their counterclaims, plaintiffs (Mutual) claimed that defendants (Tyco) delayed the entry of Mutual’s generic to the brand name drug Restoril 7.5 mg.

Econ One was retained by counsel for Mutual. Jeffrey Leitzinger was asked to define the market relevant to the analysis of the antitrust claims in this matter.  He also was asked to analyze whether the delay in Mutual’s entry as a competitor enhanced (i.e., created, increased, or maintained) monopoly power on the part of Tyco within the relevant market.  Finally, he was asked to calculate Mutual’s lost profits. Dr. Leitzinger submitted an expert report and provided deposition testimony.